Apellis Pharmaceuticals Inc — Quarterly Financial Statistics (NASDAQ:APLS) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics

Quarterly Annual

Cash from operating activities 19.36 M-53.41 M4.45 M108.47 M-14.18 M 45.33 M Cash from investing activities -20 K-8 000-49 K-148 K-108 K -313 K Cash from financing activities -4 M274 K6.56 M793 K1.26 M 8.88 M Free cash flow 19.34 M-53.42 M4.4 M108.32 M-14.28 M 45.01 M

뉴스

Gilead Expands Oncology Pipeline With $5B Tubulis Deal

FOMC To Release Minutes Of March Meeting, Delta Air Lines Earnings In Focus

3 Best Trending Stocks, According to Analysts – 4/2/2026 - TipRanks.com

Stock Market Rebounds Even As Oil Prices Skyrocket On Trump's Iran War Comments; Tesla, SpaceX, Eli Lilly In Focus: Weekly Review

Biotech Is Holding Steady In 2026 (NASDAQ:IBB)

Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio

Apellis Pharmaceuticals (APLS) Moves 135.4% Higher: Will This Strength Last?

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.49%

Biogen Acquires Apellis: Synergies, Risks, And What The Market Is Missing (NASDAQ:APLS)

Biogen Agrees $5.6B Apellis Deal as Shares Surge 136% on Announcement

Biogen Snaps Up Apellis Pharma For $5.6 Billion, But Biogen Dives As Apellis Soars

Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases